Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2011

View Archived Issues

Eli Lilly provides update on strategy and pipeline

New full dopamine D3 receptor agonist CJ-1639 displays potent and selective activity in vivo

New synthetic aminoglycoside NB-54 shows preclinical potential as Rett syndrome therapy

First potential diagnostic marker for Churg-Strauss syndrome identified

Mitsubishi Tanabe Pharma discloses new antiplatelet agents

Lundbeck patents new phosphodiesterase 10A inhibitors

Scynexis patents new ciclosporin derivatives for hepatitis C

Pierre Fabre Medicament discloses new sucrose octasulfates of zinc

New hepatocyte growth factor receptor inhibitors presented

Boehringer Ingelheim claims new inhibitors of ribosomal protein S6 kinase alpha-3

Merck Serono's new prostanoid DP2 receptor antagonist shows potential to treat asthma

Sanofi discontinues Multaq trial in patients with permanent atrial fibrillation

Pfizer Japan and Astellas Pharma revise copromotion agreement for Caduet

GSK announces regulatory update for Votrient in advanced soft tissue sarcoma

Onconova and SymBio enter license agreement for rigosertib in Japan and Korea

Sanofi and Genzyme report encouraging phase III data on alemtuzumab in MS

Generex reports preliminary results from two trials of its mealtime insulin Generex Oral-lyn

Valeant Pharmaceuticals to acquire Sanofi's Dermik dermatology unit

Coronado Biosciences secures funds to advance CNDO-201 and CNDO-109

Qiagen increases offer price for acquisition of Cellestis

HUYA Bioscience and Liaoning (Benxi) Bio-pharmaceutical Industry Base enter strategic partnership

Qiagen enters binding agreement to acquire majority stake in Ipsogen

Amarin completes nonclinical studies for AMR-101 NDA

Alkermes discontinues development of ALKS-33 in binge eating disorder based on phase II data

FDA approves Boostrix vaccine for persons over 65 years of age

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...